Less Neutropenia with Lonquex®
Non-interventional studies (NIS) are an important tool for pharmaceutical companies to test the benefit of new drugs under real-world conditions. Our customer Teva wanted to announce the positive results of the NIS “NADIR” with the innovative immunomodulator Lonquex® to the oncological community.
In cooperation with opinion leaders in oncology, we summarized the convincing study data of “NADIR” in English. Our Medical Writers often produce publications based on observational studies or registry data and are therefore very experienced in dealing with real-world data.
The work was accepted for publication in “Oncology Research and Treatment”, the official newsletter of the German Organization for Hematology and Oncology, and is an important tool for communicating the good study situation for the innovative drug Lonquex®.